Price movement over the last 24 hours
Abeona Therapeutics Inc vs Victoria's Secret & Co — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Victoria's Secret & Co trades at $76.01 (market cap $6.22B). The key difference: Victoria's Secret & Co is far larger — about 16.7× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | VSXY | |
|---|---|---|
Market Cap | $373.32M | $6.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $88.50 |
52-Week Low | $4.17 | $17.70 |
Enterprise Value | $228.22M | $8.86B |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Victoria's Secret (VSXY) trades at $78.25, up 2.01% with strong momentum as the stock benefits from international expansion and improved fundamentals. The company has beaten earnings expectations for three consecutive quarters, with Q1 2026 EPS of $0.60 surpassing the $0.32 estimate. Technical indicators show a neutral overall signal while the stock trades near pivot point resistance at $78. Analyst consensus remains bullish with a $88.56 price target representing 13% upside potential.
The outlook appears positive with international sales growing 44.9% in Q1 2026 and margin recovery underway, though risks include competitive pressures and execution challenges in global expansion. With improving cash flow projections and shareholder support for management's strategy, VSXY offers growth potential but requires monitoring of consumer spending trends and inventory management.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →